Serve as an active partner to global medical strategic planning through participation in Pumitamig and Thoracic Cancers Asset Indication Medical Strategy (AIMS) teams and its Working Groups, launch teams, and other cross-functional teams-informing medical strategy development, driving and leveraging medical insights, and representing the voice of Field Medical (FM) teams across global markets, including alignment of engagement priorities and coordination of customer-facing activities through Medical Engagement Leads (MELs). Build strong partnerships with Global Drug Development, Health Economics and Outcomes Research (HEOR), and Medical Evidence Generation teams to ensure field medical teams are equipped with the direction, training, communication, and resources needed to support priority BMS-sponsored studies.